Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

taxplanr Apr. 1 at 8:36 PM

What do you make of this testimony in front of the German Bundestag? $PFE $BNTX $MRNA https://www.instagram.com/reel/DWmYyx1jm4u/?igsh=MTBud3hycjBvM2J4ZA==

0 · Reply

AStrokeOfLuck Apr. 1 at 4:17 PM

$PFE $BNTX $MRNA $NVAX $SPY

2 · Reply

taxplanr Apr. 1 at 2:09 PM

Gastric tumors shrinking with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-cc3?utm_source=post-email-title&publication_id=1385328&post_id=192824123&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Apr. 1 at 2:02 PM

Metastases shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-mebendazole-fenbendazole-e15?utm_source=post-email-title&publication_id=1385328&post_id=192811753&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

Pillemann1 Apr. 1 at 8:45 AM

$BNTX https://www.ecdc.europa.eu/en/covid-19/variants-concern SARS-CoV-2 variants of concern as of 27 March 2026 Variant classification serves as an important communication tool for alerting EU/EEA countries about the emergence of SARS-CoV-2 variants with concerning properties likely to impact the epidemiological situation in the EU/EEA. The ECDC Strategic Analysis of Variants in Europe (SAVE) Working Group is a multidisciplinary team comprising of ECDC Experts working in Respiratory Viruses, Microbiology, Bioinformatics, Mathematical Modelling, Epidemic Intelligence, Emergency Preparedness and Response and Vaccine-Preventable Diseases and Immunisation. Currently meetings are held once per month to assess the observed or predicted impact of currently circulating and newly emerging SARS-CoV-2 variants in the EU/EEA and globally.

0 · Reply

PolycarpFX Mar. 31 at 10:34 PM

$BNTX

0 · Reply

taxplanr Mar. 31 at 4:31 PM

Bone tumors shrinking with Ivermectin Fenbendazole and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-454?utm_source=post-email-title&publication_id=1385328&post_id=192576453&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

1 · Reply

taxplanr Mar. 30 at 2:17 PM

Cancer Free in 1.5 months with Ivermectin and Fenbendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-566?utm_campaign=email-half-post&r=18m8lm&utm_source=substack&utm_medium=email

0 · Reply

taxplanr Mar. 30 at 3:41 AM

Grok says C19 mRNA injections cause Cancer $BNTX $MRNA $PFE https://www.instagram.com/p/DWc1vbKjeD_/?igsh=cXU2eTBzYjhneG85

1 · Reply

_MoonNinja Mar. 29 at 8:19 PM

$VEEV $DG $VIV $BNTX watchlist 4

0 · Reply

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

Mar 24, 2026, 6:45 AM EDT - 9 days ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 10, 2026, 5:40 PM EDT - 22 days ago

BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 3:39 PM EDT - 23 days ago

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

Mar 10, 2026, 2:48 PM EDT - 23 days ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 1:29 PM EDT - 23 days ago

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 8:40 AM EDT - 23 days ago

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Mar 10, 2026, 7:40 AM EDT - 23 days ago

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:18 AM EDT - 23 days ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 6:50 AM EDT - 23 days ago

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:49 AM EDT - 23 days ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:45 AM EDT - 23 days ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:33 AM EDT - 23 days ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Feb 25, 2026, 9:46 AM EST - 5 weeks ago

BioNTech: The Market Is Pricing Low Oncology Success

Feb 24, 2026, 6:45 AM EST - 5 weeks ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 19, 2026, 1:25 PM EST - 6 weeks ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

Jan 28, 2026, 8:00 AM EST - 2 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 13, 2026, 10:45 PM EST - 2 months ago

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:45 AM EST - 2 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 10:00 AM EST - 2 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Dec 18, 2025, 4:45 AM EST - 3 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 9, 2025, 5:54 PM EST - 4 months ago

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 9, 2025, 7:00 AM EST - 4 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

Dec 6, 2025, 3:30 PM EST - 4 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 3, 2025, 9:01 AM EST - 4 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

Dec 1, 2025, 3:50 PM EST - 4 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Dec 1, 2025, 12:35 PM EST - 4 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

Nov 26, 2025, 7:30 AM EST - 4 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 17, 2025, 6:17 PM EST - 4 months ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 13, 2025, 5:20 PM EST - 4 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Nov 13, 2025, 11:10 AM EST - 5 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

Nov 13, 2025, 8:17 AM EST - 5 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

Nov 3, 2025, 1:44 PM EST - 5 months ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 12:46 PM EST - 5 months ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 10:29 AM EST - 5 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

Nov 3, 2025, 6:47 AM EST - 5 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:45 AM EST - 5 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 27, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 22, 2025, 6:45 AM EDT - 5 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 18, 2025, 9:30 AM EDT - 5 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

Oct 1, 2025, 6:52 PM EDT - 6 months ago

BioNTech SE, InstaDeep Ltd - Special Call

Sep 23, 2025, 6:45 AM EDT - 6 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 19, 2025, 11:40 AM EDT - 6 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

Sep 12, 2025, 1:37 PM EDT - 7 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

Sep 8, 2025, 2:01 PM EDT - 7 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

Sep 8, 2025, 11:05 AM EDT - 7 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

Sep 8, 2025, 11:00 AM EDT - 7 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 7:02 AM EDT - 7 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Sep 8, 2025, 6:45 AM EDT - 7 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

taxplanr Apr. 1 at 8:36 PM

What do you make of this testimony in front of the German Bundestag? $PFE $BNTX $MRNA https://www.instagram.com/reel/DWmYyx1jm4u/?igsh=MTBud3hycjBvM2J4ZA==

0 · Reply

AStrokeOfLuck Apr. 1 at 4:17 PM

$PFE $BNTX $MRNA $NVAX $SPY

2 · Reply

taxplanr Apr. 1 at 2:09 PM

0 · Reply

taxplanr Apr. 1 at 2:02 PM

0 · Reply

Pillemann1 Apr. 1 at 8:45 AM

0 · Reply

PolycarpFX Mar. 31 at 10:34 PM

$BNTX

0 · Reply

taxplanr Mar. 31 at 4:31 PM

1 · Reply

taxplanr Mar. 30 at 2:17 PM

0 · Reply

taxplanr Mar. 30 at 3:41 AM

Grok says C19 mRNA injections cause Cancer $BNTX $MRNA $PFE https://www.instagram.com/p/DWc1vbKjeD_/?igsh=cXU2eTBzYjhneG85

1 · Reply

_MoonNinja Mar. 29 at 8:19 PM

$VEEV $DG $VIV $BNTX watchlist 4

0 · Reply

taxplanr Mar. 27 at 7:04 PM

Ivermecting Fenbendazole and Mebendazole crushing Pancreatic Tumors in Romania $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-fenbendazole-mebendazole-0ea?utm_source=post-email-title&publication_id=1385328&post_id=192340675&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Mar. 27 at 6:06 PM

Ivermectin and Fenbendazole taking care of Lung Cancer $BNTX $MRNA $MRK $PFE https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-031?utm_source=post-email-title&publication_id=1385328&post_id=192330724&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Mar. 27 at 3:26 AM

C19 mRNA injections causing cancer CDC data $BNTX $MRNA $PFE https://www.instagram.com/reel/DWW1IZ0mkRJ/?igsh=MWt0M3ZvdndjcXI4eQ==

0 · Reply

taxplanr Mar. 26 at 1:51 PM

Beating Pancreatic Cancer in 12 months with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-568?utm_source=post-email-title&publication_id=1385328&post_id=192144835&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

twincam Mar. 26 at 12:40 PM

$BMY $RVMD $JANX $BNTX $BMY facing major patent cliffs (Eliquis, Opdivo) → forced to backfill with late-stage assets. Most strategic fits = oncology + next-gen IO + targeted therapies: $RVMD (KRAS Phase )$JANX (T-cell engagers, partnered), $BNTX (late-stage IO combos). Watch for: Phase 3 data + unusual call flow = early M&A signals. Big Pharma not optional here… it’s replace revenue or lose it.

0 · Reply

Vladdavceo Mar. 25 at 10:29 PM

$BNTX https://hackernoon.com/i-wired-800000-living-neurons-into-an-llm-heres-what-actually-happened $BIOLLM.X #BioLLM http://BioLLM.com $SOUN

0 · Reply

CarolSoukup997 Mar. 25 at 9:23 PM

$BNTX $BMY $IBRX ngl imo it may be worth watching how those partnerships impact pipeline timing rather than calling it bearish right away btw

0 · Reply

taxplanr Mar. 25 at 9:18 PM

$BNTX $MRNA $PFE $MRK

0 · Reply

wheresdannynow Mar. 25 at 6:39 PM

mRNA headlines belong to $MRNA $BNTX, but innovation runs deeper. $BIOV’s DPX just landed a vet collab and delivered encouraging ovarian and bladder data. Bullish long-term setup. https://finance.yahoo.com/news/biovaxys-ai-guided-mrna-immunotherapy-120000399.html

0 · Reply

NasdaqPulse Mar. 25 at 4:38 PM

$BNTX — JEFFERIES SAYS BUY! $138 PT! While the market sleeps on BioNTech, the pros are holding the line. Jefferies reiterates BUY with a $138 price target. Current: $88.64 Upside to PT: +55.7% 50dma: $104.95 — that's $16 ABOVE current price This is a DISCONNECT. The stock is trading 15% below its 50dma. The last time we saw this setup? It ripped. The mRNA machine is bigger than COVID. Oncology pipeline. Personalized cancer therapies. This is a $21B company with a massive cash pile and the most advanced mRNA platform on the planet. 13 Buy ratings. 4 Holds. 1 Sell. The market is pricing this like it's 2022. It's not. Accumulate aggressively below $90.

0 · Reply

taxplanr Mar. 25 at 1:50 PM

Albania using Ivermectin and Mebendazole against Ovarian Cancer $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-593?utm_source=post-email-title&publication_id=1385328&post_id=192092854&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

taxplanr Mar. 25 at 12:43 PM

The most enlightening interview yet of the failures of the globalists COVID plandemic yet $BNTX $MRNA $PFE Reminds me of Jesus saying "it will be upon them before they know it" https://www.instagram.com/reel/DWRmWgsEnU2/?igsh=MXFhZzI0NmFuZGE1dg==

0 · Reply

Market Cap	22.34B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.01

Volume	786,349
Avg Vol	1,200,638
Day's Range	N/A - N/A
Shares Out	251.33M
Stochastic %K	75%
Beta	1.51
Analysts	Strong Sell
Price Target	$136.68